NCT07730788 Reflectance Confocal Microscopy Evaluation of Skin Structure of Patients With Atopic Dermatitis Under Nemolizumab
| NCT ID | NCT07730788 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hôpitaux Drôme Nord |
| Condition | Atopic Dermatitis (AD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 15 participants |
| Start Date | 2026-06-11 |
| Primary Completion | 2027-06-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15 participants in total. It began in 2026-06-11 with a primary completion date of 2027-06-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Atopic dermatitis (AD) is a chronic inflammatory skin disease with pruritus and recurrence of eczematous eruptions. Evaluation of response to treatment are only clinical using Eczema Area Severity Index (EASI), SCOring of Atopic Dermatitis Index (SCORAD) scores, with a risk of intra-observer variations. Nemolizumab is a a humanised anti-IL-31 monoclonal antibody that has proven to be effective and well-tolerated for the treatment of patients with moderate-to-severe AD. Reflectance confocal microscopy (RCM) is a noninvasive procedure that allows to evaluate epidermis and papillary dermis at a cellular level. RCM allows skin structural and inflammatory parameters evaluation. The aim of this study is to evaluate by RCM skin modifications of AD patients treated with nemolizumab.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years and older. * Patients with moderate-to-severe Atopic Dermatitis who require systemic treatment with nemolizumab * Patients affiliated with or entitled to a social security scheme. * Patients capable of giving informed consent. * Patients who have received informed information about the study and have co-signed an informed consent form for participation in the study, along with the investigator. Exclusion Criteria: * Patients who refuse to participate in the study and legally incapacitated adults * Patients with an uncontrolled chronic disease that may require corticosteroid courses/treatment. * Patients with a severe concomitant disease that, in the investigator's opinion, would negatively affect participation in the study.
Frequently Asked Questions
Who can join the NCT07730788 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atopic Dermatitis (AD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07730788 currently recruiting?
Yes, NCT07730788 is actively recruiting participants. Visit ClinicalTrials.gov or contact Hôpitaux Drôme Nord to inquire about joining.
Where is the NCT07730788 trial being conducted?
This trial is being conducted at Romans-sur-Isère, France.
Who is sponsoring the NCT07730788 clinical trial?
NCT07730788 is sponsored by Hôpitaux Drôme Nord. The trial plans to enroll 15 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.